Akari Therapeutics (AKTX) Operating Expenses (2014 - 2026)

Akari Therapeutics (AKTX) has 9 years of Operating Expenses data on file, last reported at $15.8 million in Q1 2026.

• Quarterly Operating Expenses rose 347.04% year-over-year to $15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 80.41% YoY) and the FY2025 annual result came in at $17.3 million, down 20.18% from the prior year.
• Operating Expenses climbed to $15.8 million in Q1 2026 per AKTX's latest filing, from $3.2 million in the prior quarter.
• The five-year high for Operating Expenses was $112.0 million in Q4 2024, with the low at $2.2 million in Q3 2025.
• Average Operating Expenses over 4 years is $13.2 million, with a median of $4.6 million recorded in 2023.
• Year-over-year, Operating Expenses jumped 2100.12% in 2024 and tumbled 97.12% in 2025.
• Akari Therapeutics' Operating Expenses stood at $5.1 million in 2023, then jumped by 2100.12% to $112.0 million in 2024, then plunged by 97.12% to $3.2 million in 2025, then surged by 388.32% to $15.8 million in 2026.
• Business Quant data shows AKTX's Operating Expenses at $15.8 million in Q1 2026, $3.2 million in Q4 2025, and $2.2 million in Q3 2025.